NCI Considers ‘Decentralization’ Of Group C To Provide Wider Access, Local Flexibility
In Brief: Broder Invokes Cancer Act Provision To Inform Hammer, Bush Of Potential Damage Of 32% Cut
Lasagna Committee Report Advocates Faster Drug approval, Insurance Coverage For Investigational Drugs, Ancillary Costs
Don’t Blame FDA For All Problems, Broder Says
Outside Experts Might Lengthen NDA Approval, Peck Asserts
Freement Lists Steps For Dealing With Disadvantaged
Trending Stories
- Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable” - Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Lou Weiner to step down as director of Georgetown’s Lombardi CCC after 18 years
- After a year, Stephenson institute sees a broader role in funding pancreatic cancer research, fostering collaborations
“We are not just funding research. We are building a trusted community.” - Trump administration announces “major crackdown” on healthcare fraud
- FDA issues draft guidance on accelerating development of individualized therapies for ultra-rare diseases









